TY - JOUR T1 - Blockade of Ethanol-Induced Potentiation of Glycine Receptors by a Peptide That Interferes with Gβγ Binding JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther SP - 933 LP - 939 DO - 10.1124/jpet.109.160440 VL - 331 IS - 3 AU - Leonardo Guzman AU - Gustavo Moraga-Cid AU - Ariel Avila AU - Maximiliano Figueroa AU - Gonzalo E. Yevenes AU - Jorge Fuentealba AU - Luis G. Aguayo Y1 - 2009/12/01 UR - http://jpet.aspetjournals.org/content/331/3/933.abstract N2 - The large intracellular loop (IL) of the glycine receptor (GlyR) interacts with various signaling proteins and plays a fundamental role in trafficking and regulation of several receptor properties, including a direct interaction with Gβγ. In the present study, we found that mutation of basic residues in the N-terminal region of the IL reduced the binding of Gβγ to 21 ± 10% of control. Two basic residues in the C-terminal region, on the other hand, contributed to a smaller extent to Gβγ binding. Using docking analysis, we found that both basic regions of the IL bind in nearby regions to the Gβγ dimer, within an area of high density of amino acids having an electronegative character. Thereafter, we generated a 17-amino acid peptide with the N-terminal sequence of the wild-type IL (RQH) that was able to inhibit the in vitro binding of Gβγ to GlyRs to 57 ± 5% of control in glutathione S-transferase pull-down assays using purified proteins. More interestingly, when the peptide was intracellularly applied to human embryonic kidney 293 cells, it inhibited the Gβγ-mediated modulations of G protein-coupled inwardly rectifying potassium channel by baclofen (24 ± 14% of control) and attenuated the GlyR potentiation by ethanol (51 ± 10% versus 10 ± 3%).© 2009 by The American Society for Pharmacology and Experimental Therapeutics ER -